Oppenheimer analyst Justin Kim raised the firm’s price target on Immunocore to $87 from $85 and keeps an Outperform rating on the shares following quarterly results. Looking into 2024, the firm focus on data updates for the PRAME franchise, namely Q2 updated Phase 1 in cutaneous melanoma; Q3 ovarian; and Q4 NSCLC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore Holdings Q4 and Full-Year 2023 Earnings Presentation
- Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- Immunocore reports Q4 EPS (40c), consensus (28c)
- Immunocore enters trial collaboration, supply agreement with Bristol Myers
- Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
